WO2010124018A1 - FRAGMENTATION RESISTANT IgG1 Fc-CONJUGATES - Google Patents
FRAGMENTATION RESISTANT IgG1 Fc-CONJUGATES Download PDFInfo
- Publication number
- WO2010124018A1 WO2010124018A1 PCT/US2010/031933 US2010031933W WO2010124018A1 WO 2010124018 A1 WO2010124018 A1 WO 2010124018A1 US 2010031933 W US2010031933 W US 2010031933W WO 2010124018 A1 WO2010124018 A1 WO 2010124018A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- conjugate
- hinge
- iggl
- antibody
- radical
- Prior art date
Links
- 238000013467 fragmentation Methods 0.000 title claims abstract description 51
- 238000006062 fragmentation reaction Methods 0.000 title claims abstract description 51
- 230000001404 mediated effect Effects 0.000 claims abstract description 25
- 210000004027 cell Anatomy 0.000 claims description 67
- 150000007523 nucleic acids Chemical class 0.000 claims description 39
- 102000039446 nucleic acids Human genes 0.000 claims description 37
- 108020004707 nucleic acids Proteins 0.000 claims description 37
- 239000013604 expression vector Substances 0.000 claims description 21
- 239000013598 vector Substances 0.000 claims description 13
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 10
- 108091033319 polynucleotide Proteins 0.000 claims description 10
- 239000002157 polynucleotide Substances 0.000 claims description 10
- 102000040430 polynucleotide Human genes 0.000 claims description 10
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 claims description 8
- 239000003937 drug carrier Substances 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims description 4
- 238000012258 culturing Methods 0.000 claims description 3
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 2
- 230000004927 fusion Effects 0.000 claims description 2
- 102000009109 Fc receptors Human genes 0.000 claims 1
- 108010087819 Fc receptors Proteins 0.000 claims 1
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 18
- 239000000203 mixture Substances 0.000 abstract description 15
- 230000002776 aggregation Effects 0.000 abstract description 6
- 238000004220 aggregation Methods 0.000 abstract description 6
- 150000003254 radicals Chemical class 0.000 description 62
- 108090000623 proteins and genes Proteins 0.000 description 40
- 238000003776 cleavage reaction Methods 0.000 description 38
- 230000007017 scission Effects 0.000 description 37
- 102000004169 proteins and genes Human genes 0.000 description 31
- 235000018102 proteins Nutrition 0.000 description 29
- 108090000765 processed proteins & peptides Proteins 0.000 description 27
- 230000014509 gene expression Effects 0.000 description 19
- 238000006243 chemical reaction Methods 0.000 description 18
- 230000001105 regulatory effect Effects 0.000 description 17
- 230000001225 therapeutic effect Effects 0.000 description 14
- 102000004196 processed proteins & peptides Human genes 0.000 description 13
- 241000894007 species Species 0.000 description 13
- -1 alkyl hydroperoxides Chemical class 0.000 description 12
- 230000015572 biosynthetic process Effects 0.000 description 12
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N Glutamine Chemical compound OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 11
- 108060003951 Immunoglobulin Proteins 0.000 description 11
- 238000009739 binding Methods 0.000 description 11
- 239000012634 fragment Substances 0.000 description 11
- 102000018358 immunoglobulin Human genes 0.000 description 11
- 229920001184 polypeptide Polymers 0.000 description 11
- 238000011282 treatment Methods 0.000 description 11
- 230000027455 binding Effects 0.000 description 10
- 238000000338 in vitro Methods 0.000 description 10
- 230000036961 partial effect Effects 0.000 description 10
- 238000001542 size-exclusion chromatography Methods 0.000 description 10
- 239000003642 reactive oxygen metabolite Substances 0.000 description 9
- HDFGOPSGAURCEO-UHFFFAOYSA-N N-ethylmaleimide Chemical compound CCN1C(=O)C=CC1=O HDFGOPSGAURCEO-UHFFFAOYSA-N 0.000 description 8
- 235000001014 amino acid Nutrition 0.000 description 8
- 229940024606 amino acid Drugs 0.000 description 8
- 150000001413 amino acids Chemical class 0.000 description 8
- 238000004949 mass spectrometry Methods 0.000 description 8
- 230000004048 modification Effects 0.000 description 8
- 238000012986 modification Methods 0.000 description 8
- 230000003647 oxidation Effects 0.000 description 8
- 238000007254 oxidation reaction Methods 0.000 description 8
- 102000005962 receptors Human genes 0.000 description 8
- 108020003175 receptors Proteins 0.000 description 8
- GHAZCVNUKKZTLG-UHFFFAOYSA-N N-ethyl-succinimide Natural products CCN1C(=O)CCC1=O GHAZCVNUKKZTLG-UHFFFAOYSA-N 0.000 description 7
- 238000011534 incubation Methods 0.000 description 7
- 230000007246 mechanism Effects 0.000 description 7
- 238000006467 substitution reaction Methods 0.000 description 7
- 102000000844 Cell Surface Receptors Human genes 0.000 description 6
- 108010001857 Cell Surface Receptors Proteins 0.000 description 6
- 108010076504 Protein Sorting Signals Proteins 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 230000000295 complement effect Effects 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 125000005647 linker group Chemical group 0.000 description 6
- 230000036542 oxidative stress Effects 0.000 description 6
- 108010022394 Threonine synthase Proteins 0.000 description 5
- 229910052799 carbon Inorganic materials 0.000 description 5
- 102000004419 dihydrofolate reductase Human genes 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 239000003550 marker Substances 0.000 description 5
- 239000008194 pharmaceutical composition Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 230000027756 respiratory electron transport chain Effects 0.000 description 5
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 4
- 125000000729 N-terminal amino-acid group Chemical group 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- 102000002259 TNF-Related Apoptosis-Inducing Ligand Receptors Human genes 0.000 description 4
- 235000018417 cysteine Nutrition 0.000 description 4
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 4
- 238000012217 deletion Methods 0.000 description 4
- 230000037430 deletion Effects 0.000 description 4
- 229940072221 immunoglobulins Drugs 0.000 description 4
- 238000011275 oncology therapy Methods 0.000 description 4
- 230000037361 pathway Effects 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 230000006318 protein oxidation Effects 0.000 description 4
- 230000009870 specific binding Effects 0.000 description 4
- RVEZZJVBDQCTEF-UHFFFAOYSA-N sulfenic acid Chemical compound SO RVEZZJVBDQCTEF-UHFFFAOYSA-N 0.000 description 4
- KIUMMUBSPKGMOY-UHFFFAOYSA-N 3,3'-Dithiobis(6-nitrobenzoic acid) Chemical compound C1=C([N+]([O-])=O)C(C(=O)O)=CC(SSC=2C=C(C(=CC=2)[N+]([O-])=O)C(O)=O)=C1 KIUMMUBSPKGMOY-UHFFFAOYSA-N 0.000 description 3
- 102000016938 Catalase Human genes 0.000 description 3
- 108010053835 Catalase Proteins 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 3
- 101001018085 Lysobacter enzymogenes Lysyl endopeptidase Proteins 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 229910006069 SO3H Inorganic materials 0.000 description 3
- 108010000449 TNF-Related Apoptosis-Inducing Ligand Receptors Proteins 0.000 description 3
- 238000007792 addition Methods 0.000 description 3
- 125000003275 alpha amino acid group Chemical group 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 230000008827 biological function Effects 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 239000012512 bulk drug substance Substances 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 229960001484 edetic acid Drugs 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 210000004602 germ cell Anatomy 0.000 description 3
- 210000004408 hybridoma Anatomy 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 150000004680 hydrogen peroxides Chemical class 0.000 description 3
- 125000002883 imidazolyl group Chemical group 0.000 description 3
- 238000003018 immunoassay Methods 0.000 description 3
- 238000002703 mutagenesis Methods 0.000 description 3
- 231100000350 mutagenesis Toxicity 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 125000003396 thiol group Chemical group [H]S* 0.000 description 3
- 150000003573 thiols Chemical class 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 230000009261 transgenic effect Effects 0.000 description 3
- 229910052723 transition metal Inorganic materials 0.000 description 3
- 150000003624 transition metals Chemical class 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 2
- 241000699802 Cricetulus griseus Species 0.000 description 2
- 241000701022 Cytomegalovirus Species 0.000 description 2
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 2
- 241000206602 Eukaryota Species 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 2
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 2
- 102100030856 Myoglobin Human genes 0.000 description 2
- 108010062374 Myoglobin Proteins 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
- 230000029936 alkylation Effects 0.000 description 2
- 238000005804 alkylation reaction Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000010504 bond cleavage reaction Methods 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- OPQARKPSCNTWTJ-UHFFFAOYSA-L copper(ii) acetate Chemical compound [Cu+2].CC([O-])=O.CC([O-])=O OPQARKPSCNTWTJ-UHFFFAOYSA-L 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 239000002254 cytotoxic agent Substances 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000000132 electrospray ionisation Methods 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 230000009851 immunogenic response Effects 0.000 description 2
- IQPQWNKOIGAROB-UHFFFAOYSA-N isocyanate group Chemical group [N-]=C=O IQPQWNKOIGAROB-UHFFFAOYSA-N 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 229960000485 methotrexate Drugs 0.000 description 2
- 201000000050 myeloid neoplasm Diseases 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- 238000010525 oxidative degradation reaction Methods 0.000 description 2
- 230000001590 oxidative effect Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000010188 recombinant method Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 238000004007 reversed phase HPLC Methods 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- BUUPQKDIAURBJP-UHFFFAOYSA-N sulfinic acid Chemical compound OS=O BUUPQKDIAURBJP-UHFFFAOYSA-N 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- DVPIKQUDWCILSQ-UHFFFAOYSA-N 5,5-dimethyl-1-pyrroline Chemical compound CC1(C)CCC=N1 DVPIKQUDWCILSQ-UHFFFAOYSA-N 0.000 description 1
- 230000005730 ADP ribosylation Effects 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 108091029865 Exogenous DNA Proteins 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 101150074355 GS gene Proteins 0.000 description 1
- 102100021519 Hemoglobin subunit beta Human genes 0.000 description 1
- 108091005904 Hemoglobin subunit beta Proteins 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101000635799 Homo sapiens Run domain Beclin-1-interacting and cysteine-rich domain-containing protein Proteins 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 1
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 125000003877 L-cysteinyl radical group Chemical group 0.000 description 1
- 125000000205 L-threonino group Chemical group [H]OC(=O)[C@@]([H])(N([H])[*])[C@](C([H])([H])[H])([H])O[H] 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 108010057466 NF-kappa B Proteins 0.000 description 1
- 102000003945 NF-kappa B Human genes 0.000 description 1
- 241001045988 Neogene Species 0.000 description 1
- 244000061176 Nicotiana tabacum Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 102100030852 Run domain Beclin-1-interacting and cysteine-rich domain-containing protein Human genes 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 240000003768 Solanum lycopersicum Species 0.000 description 1
- 102000050000 TIE-1 Receptor Human genes 0.000 description 1
- 108010090089 TIE-1 Receptor Proteins 0.000 description 1
- 108010090091 TIE-2 Receptor Proteins 0.000 description 1
- 102000012753 TIE-2 Receptor Human genes 0.000 description 1
- 108091007178 TNFRSF10A Proteins 0.000 description 1
- 108090000848 Ubiquitin Proteins 0.000 description 1
- 102000044159 Ubiquitin Human genes 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 230000001270 agonistic effect Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 239000001166 ammonium sulphate Substances 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 239000003124 biologic agent Substances 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229960001714 calcium phosphate Drugs 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000004186 co-expression Effects 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 230000001268 conjugating effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000000599 controlled substance Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 1
- 229910000366 copper(II) sulfate Inorganic materials 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 239000000824 cytostatic agent Substances 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000012502 diagnostic product Substances 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000003920 environmental process Methods 0.000 description 1
- 238000002270 exclusion chromatography Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 230000006251 gamma-carboxylation Effects 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 238000003505 heat denaturation Methods 0.000 description 1
- 238000000589 high-performance liquid chromatography-mass spectrometry Methods 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000012872 hydroxylapatite chromatography Methods 0.000 description 1
- 230000033444 hydroxylation Effects 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 239000002596 immunotoxin Substances 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 229940055742 indium-111 Drugs 0.000 description 1
- APFVFJFRJDLVQX-AHCXROLUSA-N indium-111 Chemical compound [111In] APFVFJFRJDLVQX-AHCXROLUSA-N 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 239000012948 isocyanate Substances 0.000 description 1
- 150000002513 isocyanates Chemical class 0.000 description 1
- 238000001155 isoelectric focusing Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 150000004715 keto acids Chemical group 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 238000001823 molecular biology technique Methods 0.000 description 1
- 101150091879 neo gene Proteins 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 238000002515 oligonucleotide synthesis Methods 0.000 description 1
- 238000012510 peptide mapping method Methods 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 150000008300 phosphoramidites Chemical class 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000011533 pre-incubation Methods 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000006950 reactive oxygen species formation Effects 0.000 description 1
- 108091006084 receptor activators Proteins 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000004017 serum-free culture medium Substances 0.000 description 1
- 230000007781 signaling event Effects 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000019635 sulfation Effects 0.000 description 1
- 238000005670 sulfation reaction Methods 0.000 description 1
- 125000004646 sulfenyl group Chemical group S(*)* 0.000 description 1
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 230000003319 supportive effect Effects 0.000 description 1
- 230000005469 synchrotron radiation Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000006276 transfer reaction Methods 0.000 description 1
- 229910001428 transition metal ion Inorganic materials 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Definitions
- the present invention relates to immunoglobulins for use in therapeutic and diagnostic applications which are resistant to fragmentation from reactive oxygen species.
- Human immunoglobulin (IgG) molecules consist of two identical copies of light chains (LCs) and heavy chains (HCs). An inter-chain disulfide bond between the LC and HC connects them to form a half antibody; the HCs of the two identical copies of the half antibody are connected by disulfide bonds in a so-called hinge sequence to form the native antibody.
- the human IgGl hinge sequence includes two pairs of cysteine (Cys) residues that can form two separate disulfide bonds.
- Cys cysteine residues
- ROS Reactive oxygen species
- Proteins that are regulated by H 2 O 2 have characteristic cysteines, which are sensitive to oxidation because their environment promotes ionization of the thiol group (Cys-SH) to the thiolate anion (Cys-S ⁇ ), which is more readily oxidized to sulfenic acid (Cys-SOH) than Cys-SH.
- the sulfenic acid is unstable and either reacts with any accessible thiol to form a disulfide or undergoes further oxidation to sulfinic acid (Cys- SO 2 H) or sulfonic aid (CVS-SO3H) Kice, J. L, Adv. Phys. Org. Chem. 17: 65, 1980; Claiborne, A., Biochemistry 38: 15407-15412, 1999.
- Cysteine-based radicals can be formed by either short-range hydrogen atom abstraction or one-electron transfer reactions. Giles, N. M. et al., Chemistry & Biology 10: 677- 693, 2003; Garrison, W. M., Chem. Rev., 87: 381-398, 1987; Bonifacic, M. et al., J. Chem. Soc. Pekin Trans., 2: 675-685, 1975; Elliot, A. J. et al., J. Phys. Chem. 85: 68-75, 1981; Jacob, C. et al., Biol. Chem. 387: 1385-1397, 2006.
- ROS reactive oxygen species
- ROS can lead to radical-mediated fragmentation and aggregation of proteins in vitro as well as in vivo. These oxidative modifications can reduce manufacturing yield of therapeutic and diagnostic products as well as reduce their efficacy.
- Antibodies have proven to be a particularly useful class of therapeutic and diagnostic proteins.
- the Fc hinge region of antibodies is prone to oxidative modification. This vulnerability to radical attack makes stabilization of the Fc hinge region a priority for the therapeutic and diagnostic development of antibody candidates as well as Fc-conjugated compounds in general.
- the present invention provides an immunoglobulin Fc comprising a hinge sequence of the IgGl or IgG3 class which is resistant to radical-mediated fragmentation. Fragmentation resistance is manifested in a reduction in disulfide bond cleavage which would otherwise result in two half-antibodies, as well as a reduction in fragmentation events within the polypeptides making up each of these half antibodies.
- the invention is an Fc-conjugate wherein the Fc is a human IgGl or IgG3 Fc.
- the IgGl and IgG3 Fc comprise a hinge core sequence which in one-letter amino acid code is THTCPXCP, wherein X represents an R or P residue.
- the H (histidine) residue in the hinge core sequence of native IgGl or IgG3 Fc is substituted with a Ser (serine), GIn (glutamine), Asn (asparagine), or Thr (threonine) residue.
- the Fc-conjugate is in a pharmaceutically acceptable carrier.
- the present invention is also directed to an isolated nucleic acid comprising a polynucleotide encoding the Fc or the Fc-conjugate of the present invention, as well as an expression vector comprising the isolated nucleic acid, and a host cell comprising the aforementioned expression vector.
- the present invention also includes compositions and methods of making the Fc or Fc-conjugate of the invention which can entail culturing in a suitable host cell the expression vector comprising the nucleic acid of the invention under conditions suitable to express the nucleic acid, and isolating the expressed Fc or Fc-conjugate from the host cell.
- Figure 1 shows the extent of radical mediated fragmentation of an IgGl antibody resulting from H 2 O 2 in combination with an additional reagent as detailed in the Examples.
- Figure 2 shows the extent of radical mediated fragmentation measured in milli-
- These fragmentation resistant IgGl and IgG3 Fc can be used in, e.g., the production of antibodies for therapeutic and diagnostic use having greater resistance to in vitro or in vivo fragmentation or aggregation.
- Compositions of the invention include: Fc-conjugates, polynucleotides comprising nucleic acids encoding the Fc or Fc- conjugates of the invention, vectors comprising these nucleic acids, host cells comprising and host cells expressing these vectors, and pharmaceutical compositions. Methods of making, and using, each of these compositions are also provided.
- the term "antibody” includes reference to both glycosylated and non-glycosylated immunoglobulins of any isotype or subclass, including human (e.g., CDR- grafted), humanized, chimeric, multi-specific, monoclonal, polyclonal, and oligomers thereof, irrespective of whether such antibodies are produced, in whole or in part, via immunization, through recombinant technology, by way of in vitro synthetic means, or otherwise.
- the term "antibody” in inclusive of those that are prepared, expressed, created or isolated by recombinant means such as (a) antibodies isolated from an animal (e.g., a mouse) that is transgenic for human immunoglobulin genes or a hybridoma prepared therefrom, (b) antibodies isolated from a host cell transfected to express the antibody (e.g., from a transfectoma), (c) antibodies isolated from a recombinant, combinatorial antibody library, and (d) antibodies prepared, expressed, created or isolated by any other means that involve splicing of immunoglobulin gene sequences to other DNA sequences.
- Such antibodies have variable and constant regions derived from germline immunoglobulin sequences of two distinct species of animals.
- such antibodies can be subjected to in vitro mutagenesis (or, when an animal transgenic for human immunoglobulin sequences is used, in vivo somatic mutagenesis) and thus the amino acid sequences of the V H and V L regions of the antibodies are sequences that, while derived from and related to the germline V H and V L sequences of a particular species (e.g., human), may not naturally exist within that species' antibody germline repertoire in vivo.
- in vitro mutagenesis or, when an animal transgenic for human immunoglobulin sequences is used, in vivo somatic mutagenesis
- conjugate means any chemical or biological moiety that, when conjugated to an Fc serves a diagnostic or therapeutic function.
- the conjugate can be directly or indirectly (i.e., through a chemical spacer) covalently attached.
- exemplary conjugates include: cytotoxic or cytostatic agents (e.g., anti-tumor or anti-angiogenic agents), polyethylene glycol, lipids, and receptor or receptor fragments such as the extracellular domain of a cell-surface receptor.
- a "host cell” is a cell that can be used to express a nucleic acid, e.g., a nucleic acid of the present invention.
- a host cell can be a prokaryote, for example, E. coli, or it can be a eukaryote, for example, a single-celled eukaryote (e.g., a yeast or other fungus), a plant cell (e.g., a tobacco or tomato plant cell), an animal cell (e.g., a human cell, a monkey cell, a hamster cell, a rat cell, a mouse cell, or an insect cell) or a hybridoma.
- a prokaryote for example, E. coli
- a eukaryote for example, a single-celled eukaryote (e.g., a yeast or other fungus)
- a plant cell e.g., a tobacco or tomato plant cell
- host cells examples include the COS- 7 line of monkey kidney cells (ATCC CRL 1651) (see Gluzman et al, Cell 23: 175, 1981), L cells, C 127 cells, 3T3 cells (ATCC CCL 163), Chinese hamster ovary (CHO) cells or their derivatives such as Veggie CHO and related cell lines which grow in serum-free media (see Rasmussen et al., Cytotechnology 28: 31, 1998) or CHO strain DX-Bl 1, which is deficient in DHFR (see Urlaub et al., Proc. Natl. Acad. Sci. USA 11: 4216-4220, 1980).
- COS- 7 line of monkey kidney cells ATCC CRL 1651
- L cells C 127 cells
- 3T3 cells ATCC CCL 163
- CHO Chinese hamster ovary
- CHO Chinese ovary
- a host cell is a cultured cell that can be trans fected with a polypeptide- encoding nucleic acid, which can then be expressed in the host cell.
- the phrase "recombinant host cell” can be used to denote a host cell that has been transfected with a nucleic acid to be expressed.
- a host cell comprises the nucleic acid but does not express it at an appreciable level unless a regulatory sequence is introduced into the host cell such that the regulatory sequence becomes operably linked with the nucleic acid. It is understood that the term host cell refers not only to the particular subject cell but to the progeny or potential progeny of such a cell. Because certain modifications may occur in succeeding generations due to either mutation or environmental influences, such progeny may not, in fact, be identical to the parent cell, but are still included within the scope of the term as used herein.
- human antibody refers to an antibody in which both the constant regions and the framework consist of fully or substantially human sequences such that the human antibody elicits substantially no immunogenic reaction against itself when administered to a human host and preferably, no detectable immunogenic reaction.
- humanized antibody refers to an antibody in which substantially all of the constant region is derived from or corresponds to human immunoglobulins, while all or part of one or more variable regions is derived from another species, for example a mouse.
- isolated in the context of a nucleic acid means DNA or RNA which as a result of direct human intervention: 1) is integrated into a locus of a genome where it is not found in nature, 2) is operably linked to a nucleic acid to which it is not operably linked to in nature, or, 3) is substantially purified (e.g., at least 70%, 80%, or 90%) away from cellular components with which it is admixed in its native state.
- isolated in the context of an Fc or Fc-conjugate means : ( 1 ) is substantially purified (e.g., at least 60%, 70%, 80%, or 90%) away from cellular components with which it is admixed in its expressed state such that it is the predominant species present, (2) is conjugated to a polypeptide or other moiety to which it is not linked in nature, (3) does not occur in nature as part of a larger polypeptide sequence, (4) is combined with other chemical or biological agents having different specificities in a well-defined composition, or (5) comprises a human engineered sequence not otherwise found in nature.
- monoclonal antibody or “monoclonal antibody composition” as used herein refer to a preparation of antibody molecules of single molecular composition, typically encoded by the same nucleic acid molecule.
- a monoclonal antibody composition displays a single binding specificity and affinity for a particular epitope.
- monoclonal antibodies are produced by a single hybridoma or other cell line (e.g., a transfectoma), or by a transgenic mammal.
- the term “monoclonal” is not limited to any particular method for making an antibody.
- nucleic acid and polynucleotide includes reference to a deoxyribonucleotide or ribonucleotide polymer, or chimeras thereof, and unless otherwise limited, encompasses the complementary strand of the referenced sequence.
- a nucleic acid sequence is "operably linked" to a regulatory sequence if the regulatory sequence affects the expression (e.g., the level, timing, or location of expression) of the nucleic sequence.
- a "regulatory sequence” is a nucleic acid that affects the expression (e.g., the level, timing, or location of expression) of a second nucleic acid.
- a regulatory sequence and a second sequence are operably linked if a functional linkage between the regulatory sequence and the second sequence is such that the regulatory sequence initiates and mediates transcription of the DNA sequence corresponding to the second sequence.
- regulatory sequences include promoters, enhancers and other expression control elements (e.g., polyadenylation signals).
- peptide refers to a molecule comprising two or more amino acid residues joined to each other by peptide bonds.
- polypeptide and “protein” are also inclusive of modifications including, but not limited to, glycosylation, lipid attachment, sulfation, gamma- carboxylation of glutamic acid residues, hydroxylation and ADP-ribosylation.
- nucleic acid refers to DNA molecules (e.g., cDNA or genomic DNA), RNA molecules (e.g., mRNA), and hybrids thereof.
- DNA molecules e.g., cDNA or genomic DNA
- RNA molecules e.g., mRNA
- the nucleic acid molecule can be single-stranded or double-stranded.
- telomere binding reaction As used herein, “specifically binds” or “specifically binding” or “binds specifically” refers to a binding reaction which is determinative of the presence of the target (e.g., a protein) in the presence of a heterogeneous population of proteins and other biologies.
- the specified Fc-conjugates such as antibodies or peptibodies, or other binding polypeptides bind to a particular protein and do not bind in a statistically significant amount to other proteins present in the sample.
- Fc-conjugates e.g., antibodies, peptibodies
- Fc-conjugates are selected for their ability to specifically bind to a protein by screening methods (e.g., phage display) or by immunization using the protein or an epitope thereof. See, Harlow and Lane (1998), Antibodies, A Laboratory Manual, Cold Spring Harbor Publications, New York, for a description of immunoassay formats that can be used to determine specific binding.
- solid-phase ELISA immunoassays can be used to determine specific binding. Specific binding proceeds with an association constant of at least about 1 x 10 7 M "1 , and often at least 1 x 10 8 M "1 , 1 x 10 9 M "1 , or, 1 x 10 10 M "1 .
- vector includes reference to a nucleic acid used in the introduction of a polynucleotide of the present invention into a host cell.
- Vectors are often replicons.
- Expression vectors permit transcription of a nucleic acid inserted therein when present in a suitable host cell or under suitable in vitro conditions.
- the present invention provides isolated IgGl and IgG3 Fc and Fc-conjugates, and methods of making and using these compositions, that are resistant to fragmentation and/or aggregation relative to a native IgGl or IgG3 Fc.
- the mechanism of free radical-mediated fragmentation has implicated a histidine residue present in the hinge core sequence of IgGl immunoglobulins in fragmentation of the Fc.
- Appropriate substitution or deletion of that hinge core sequence histidine residue in an IgGl and IgG3 Fc can reduce the degree of radical-mediated fragmentation and/or aggregation relative to an unmodified Fc or Fc-conjugate.
- the present invention provides isolated Fc and Fc-conjugates having a modification rendering it resistant to fragmentation and/or aggregation from reactive oxygen species.
- the Fc (fragment crystallizable) of a mammalian immunoglobulin is a well characterized structure comprising a hinge region having a "hinge core sequence.”
- Table 1 shows a list of hinge core sequences, presented in one-letter amino acid code, found in human IgG subtypes. In the numbering system of Edelman et al. (Proc. Natl. Acad. Sci.
- the hinge core sequence of IgGl corresponds to the IgGl heavy chain residues 216-230 while the hinge core sequence of IgG3 corresponds to the IgG3 heavy chain residues 214-230.
- the histidine residue (“H") present in the IgGl or IgG3 hinge core sequence (at residue 224) as presented in Table 1 is substituted with a polar amino acid residue which is able to form hydrogen bonds.
- Specific examples of amino acid residues substitutable for the histidine residue in the hinge core sequence of IgGl and IgG3 are Ser, GIn, Asn, or Thr residues.
- the histidine residue is deleted from the hinge core sequence.
- Table 1 Sequence of the hinge core of IgG subtypes.
- the motif CPxCP is underlined.
- IgG2 ERKCCVECPPCP SEQ ID NO :2
- IgG4 ESKYGPPCPSCP (SEQ ID NO :4)
- the Fc of the Fc-conjugate of the present invention that is subject to the substitution or deletion yielding a radical-mediated fragmentation resistant Fc will be a human IgGl or IgG3 Fc.
- a limited number of substitutions, additions, or deletions to a human IgGl or IgG3 Fc can be made while retaining the properties of the IgG subtype.
- 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acids of the IgGl or IgG3 Fc can be modified and still be within the scope of the present invention.
- a modified IgGl or IgG3 Fc will be 95%, 96%, 97%, 98%, or 99% identical to a native human IgGl or IgG3 Fc.
- the sole modification to the IgGl or IgG3 hinge core sequence of the present invention is a substitution of the histidine residue in the hinge core sequence as described above.
- the Fc-conjugate can be monovalent or of a bivalent structure. Each conjugate of a bivalent Fc-conjugate can be the same or a different conjugate.
- Fc-conjugate can comprise or consist of a drug such as a chemotherapeutic compound, a diagnostic label such as a radiolabel, or a protein such as the extracellular domain of a human cell-surface receptor.
- the conjugate comprises or consists of an Fab antibody segment such that the Fc-conjugate is an IgGl or IgG3 antibody.
- the antibody can be polyclonal or monoclonal.
- the Fc-conjugate is a fully human monoclonal, or a humanized monoclonal with CDR (complementarity determining regions) grafted from a non-human source (e.g., murine) onto an otherwise fully human IgGl or IgG3.
- the antibody can be an agonistic or antagonistic antibody such that it activates or inhibits activation of a receptor.
- that receptor is a human cell-surface receptor wherein the Fc-conjugate specifically binds to the extracellular domain of the cell-surface receptor.
- the Fc-conjugate specifically binds to a ligand of a human cell-surface receptor such that it prevents binding of the ligand to the receptor.
- human cell-surface receptors to which the Fc-conjugates can bind include death receptor 4 (TRAIL Receptor- 1), death receptor 5 (TRAIL Receptor-2), VEGF (vascular endothelial growth factor) receptor, a TNFR (tumor necrosis factor receptor), RANK (receptor activator nuclear factor kappa b) receptor, or Tie-1 and Tie -2 receptors.
- the conjugate of the Fc-conjugate is a peptide (a "peptibody") that specifically binds to a desired target. Peptibodies are taught in the International Application having publication number WO 2000/24782 (incorporated herein by reference).
- the present invention is also directed to an isolated polynucleotide comprising a nucleic acid encoding the Fc of the Fc-conjugates of the present invention.
- a nucleic acid of the present invention can encode the Fc-protein conjugate in its entirety.
- Recombinant methods for producing the Fc and Fc-protein conjugates of the present invention commonly employ a polynucleotide comprising an isolated nucleic acid encoding the IgGl or IgG3 Fc of the present invention.
- a nucleic acid encoding an Fc-protein conjugate of the invention can be directly synthesized by methods of in vitro oligonucleotide synthesis known in the art. Alternatively, smaller fragments can be synthesized and joined to form a larger fragment using recombinant methods known in the art.
- nucleic acids primers with the desired hinge core sequence substitution or deletion are employed in PCR based in vitro mutagenesis to create the Fc or Fc-conjugates of the present invention.
- polynucleotides of the present invention can also be constructed via in vitro synthetic means (e.g., solid phase phosphoramidite synthesis), or combinations thereof. Such methods are well known to those of ordinary skill in the art. See, for example, Current Protocols in Molecular Biology, Ausubel, et al, Eds., Greene Publishing and Wiley-Interscience, New York (1995).
- isolated DNA encoding these compositions can be obtained by standard molecular biology techniques (e.g., PCR amplification, site directed mutagenesis) and can be inserted into expression vectors such that the genes are operatively linked to transcriptional and translational regulatory sequences.
- the present invention thus includes expression vectors (polynucleotides) comprising nucleic acids of the present invention.
- Expression vectors include plasmids, retroviruses, cosmids, YACs, EBV derived episomes, and the like.
- the expression vector can encode a signal peptide that facilitates secretion of the Fc or Fc-protein conjugate of the present invention from a host cell.
- the Fc or Fc-protein conjugate gene can be cloned into the vector such that the signal peptide is linked in- frame to the amino terminus of the Fc/Fc-protein conjugate gene.
- the signal peptide can be an immunoglobulin signal peptide or a heterologous signal peptide (i.e., a signal peptide from a non-immunoglobulin protein).
- the expression vector and expression control sequences are chosen to be compatible with the expression host cell used.
- a compatible vector and host cell system can allow, for example, co-expression and assembly of the variable heavy and variable light chains of an Fc-conjugate which is an antibody.
- Suitable systems for expression can be determined by those skilled in the art.
- the expression vectors are split DHFR vectors, PDC323 or PDC324; see, McGrew, J. T. and Bianchi, A. A. (2002) "Selection of cells expressing heteromeric proteins", U.S. Patent Application No. 20030082735; and, Bianchi, A. A. and McGrew, J.
- variable heavy chain nucleic acid and the antibody variable light chain nucleic acids of the present invention can be inserted into separate vectors or, frequently, both genes are inserted into the same expression vector.
- the nucleic acids can be inserted into the expression vector by standard methods (e.g., ligation of complementary restriction sites on the antibody nucleic acid fragment and vector, or blunt end ligation if no restriction sites are present).
- Nucleic acids and expression vectors of the present invention can be introduced into a host cell via transfection.
- transfection are intended to encompass a wide variety of techniques commonly used for the introduction of exogenous DNA into a prokaryotic or eukaryotic host cell, e.g., electroporation, calcium-phosphate precipitation, DEAE-dextran transfection and the like.
- Fc- conjugates of the invention in either prokaryotic or eukaryotic host cells, expression of antibodies in eukaryotic cells, and most preferably mammalian host cells, is the most typical because such eukaryotic cells, and in particular mammalian cells, are more likely than prokaryotic cells to assemble and secrete a properly folded and immunologically active antibody.
- the expression vectors of the invention carry regulatory sequences that control the expression of the sequence in a host cell.
- regulatory sequences are described, for example, in Goeddel; Gene Expression Technology. Methods in Enzymology 185, Academic Press, San Diego, Calif. (1990). It will be appreciated by those skilled in the art that the design of the expression vector, including the selection of regulatory sequences may depend on such factors as the choice of the host cell to be transformed, the level of expression of protein desired, and the like.
- Preferred regulatory sequences for mammalian host cell expression include viral elements that direct high levels of protein expression in mammalian cells, such as promoters and/or enhancers derived from cytomegalovirus (CMV), Simian Virus 40 (SV40), adenovirus, (e.g., the adenovirus major late promoter (AdMLP)) and polyoma.
- CMV cytomegalovirus
- SV40 Simian Virus 40
- AdMLP adenovirus major late promoter
- nonviral regulatory sequences may be used, such as the ubiquitin promoter or beta-globin promoter.
- the expression vectors of the invention may carry additional sequences, such as sequences that regulate replication of the vector in host cells (e.g., origins of replication) and selectable marker genes.
- the selectable marker gene facilitates selection of host cells into which the vector has been introduced (see e.g., U.S. Pat. Nos. 4,399,216, 4,634,665 and 5,179,017, all by Axel et al.).
- the selectable marker gene confers resistance to drugs, such as G418, hygromycin or methotrexate, on a host cell into which the vector has been introduced.
- Preferred selectable marker genes include the dihydrofolate reductase (DHFR) gene (for use in dhfr-host cells with methotrexate selection/amplification) and the neo gene (for G418 selection).
- DHFR dihydrofolate reductase
- Preferred mammalian host cells for expressing the Fc or Fc-conjugates of the invention include Chinese Hamster Ovary (CHO cells) (including dhfr-CHO cells, described in Urlaub and Chasin, Proc. Natl. Acad. ScL USA 77: 4216-4220, 1980, used with a DHFR selectable marker, e.g., as described in Kaufman, R. J. and Sharp, P. A., MoI. Biol. 159: 601-621, 1982), NS/0 myeloma cells, COS cells and SP2.0 cells.
- Chinese Hamster Ovary CHO cells
- dhfr-CHO cells described in Urlaub and Chasin, Proc. Natl. Acad. ScL USA 77: 4216-4220, 1980, used with a DHFR selectable marker, e.g., as described in Kaufman, R. J. and Sharp, P. A., MoI. Biol. 159: 601-621, 1982
- Fc or Fc-conjugates are produced by culturing the host cells in the appropriate culture media for a period of time sufficient to allow for their expression in the host cells or, more preferably, secretion of the Fc or Fc-conjugate into the culture medium in which the host cells are grown.
- the Fc or Fc-conjugate can be purified for isolation according to standard methods in the art, including HPLC purification, fraction column chromatography, gel electrophoresis and the like (see, e.g., Scopes, Protein Purification, Springer- Verlag, NY, 1982).
- polypeptides are purified using chromatographic and/or electrophoretic techniques.
- Exemplary purification methods include, but are not limited to, precipitation with ammonium sulphate; precipitation with PEG; immunoprecipitation; heat denaturation followed by centrifugation; chromatography, including, but not limited to, affinity chromatography (e.g., Protein-A-Sepharose), ion exchange chromatography, exclusion chromatography, and reversed-phase chromatography; gel filtration; hydroxylapatite chromatography; isoelectric focusing; polyacrylamide gel electrophoresis; and combinations of such and other techniques.
- a polypeptide is purified by fast protein liquid chromatography or by high performance liquid chromotography (HPLC).
- the present invention provides pharmaceutical compositions comprising Fc and
- Fc-conjugates of the present invention formulated with a pharmaceutically acceptable carrier.
- the pharmaceutically acceptable carrier is suitable for administration in human subjects.
- pharmaceutically acceptable carrier includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like that are physiologically compatible when administered to a particular subject.
- Pharmaceutical compositions typically must be sterile and stable under the conditions of manufacture and storage.
- compositions of the invention can be administered in combination therapy, i.e., combined with other agents.
- Agents are inclusive of, but not limited to, in vitro synthetically prepared chemical compositions, antibodies, antigen binding regions, radionuclides, and combinations and conjugates thereof.
- Dosage regimens are adjusted to provide the optimum desired response (e.g., a therapeutic response). For example, a single bolus may be administered, several divided doses may be administered over time or the dose may be proportionally reduced or increased as indicated by the exigencies of the therapeutic situation. It is especially advantageous to formulate parenteral compositions in dosage unit form for ease of administration and uniformity of dosage.
- Dosage unit form as used herein refers to physically discrete units suited as unitary dosages for the subjects to be treated; each unit contains a predetermined quantity of active compound calculated to produce the desired therapeutic effect in association with the pharmaceutical carrier.
- the various therapeutic moieties described herein that improve the therapeutic and/or diagnostic benefit can be covalently linked, directly or indirectly (e.g., via a "linking group") to an Fc of the present invention to yield an Fc-conjugate.
- a linking group is optional.
- the linker is often made up of amino acids linked together by peptide bonds. One or more of these amino acids may be glycosylated, as is well understood by those in the art. Non-peptide linkers are also possible.
- An exemplary non-peptide linker is a PEG (polyethylene glycol) linker.
- compositions of the present invention can be coupled to radionuclides, such as 1311, 9OY, 105Rh, indium-111, etc., as described in Goldenberg, D. M. et al. Cancer Res. 41 : 4354-4360, 1981, and in EP 0365 997.
- radionuclides such as 1311, 9OY, 105Rh, indium-111, etc., as described in Goldenberg, D. M. et al. Cancer Res. 41 : 4354-4360, 1981, and in EP 0365 997.
- H2 ⁇ 2-mediated radical cleavage led to the loss of one Fab domain and the formation of a partial molecule.
- H 2 O 2 attack of the IgGl resulted in the breakage of the interchain disulfide bond between the two cysteine residues located at position 226 (Cys 226 ) in the hinge region and followed by the formation of sulfenic acid (CyS 226 SOH) and a thiyl radical (CyS 226 S * ), which initializes an electron transfer to upper hinge residues, leading to radical- mediated polypeptide backbone fragmentation.
- the antibody used was a recombinant fully human antibody of the IgG 1 subclass.
- the molecule was expressed in CHO cells and chromatographically purified using conventional techniques.
- the antibody fragments were separated by size exclusion chromatography (SEC).
- SEC size exclusion chromatography
- the cleavage of antibody was measured by a percentage of partial molecules (Cl and C2).
- a reaction mixture (1.0 mL) containing 2 mg to 10 mg of IgGl antibody in a buffer was incubated with varying concentrations OfH 2 O 2 .
- the samples were buffer exchanged by centrifugation in filter units.
- Purified partial molecules ( ⁇ 1 mg/mL) were reduced and alkylated.
- the alkylation was performed at room temperature in the dark and a 0.5 M DTT stock solution was added to quench the alkylation.
- Reversed-phase high- performance liquid chromatography (RP-HPLC) was performed followed by electrospray ionization (ESI) time-of-flight (TOF) mass spectrometry (MS).
- Purified bulk antibody was analyzed by size exclusion chromatography (SEC), and showed -0.9% of a partial molecule (Pl). This is not a single case from one lot but was present in several runs with a range of 0.9-1.1%.
- the Pl specie was further purified by SEC to purity greater than 95%, and analyzed by RP-HPLC-TOF/MS. The results indicated that Pl is a heavily oxidized partial antibody that lost one Fab domain.
- H 2 O 2 is known to be capable of causing oxidation and damage to proteins.
- H 2 O 2 was employed to treat the IgGl, and the impact was measured by SEC. Over the range of 5-20 mM H 2 O 2 , no notable cleavage was found for the first 8 hours of incubation. Only after 48 hours of incubation with 20 mM H 2 O 2 , two partial fragments — Cl and C2 — were observed. The amounts of these two fragments grew in direct proportion to the length of incubation. This fragmentation is also dependent on the antibody concentration and pH conditions. In addition, the cleavage proceeded without a significant steady phase even up to 8 weeks.
- RP-HPLC-TOF/MS analysis of the C2 fragment revealed that it is the Fab domain of the IgGl, and is heavily oxidized.
- the LC of C2 displayed a similar profile to its counterpart in Cl.
- the Fab portion of the HC (Fd) in C2 had two components, both of which were heavily oxidized with one or three oxygen additions.
- the more highly oxidized component contained a ladder of C-terminal residues Asp , Lys , Thr , His , and Thr ; the more lightly oxidized Fd component possessed a wider ladder, consisting of C-terminal residues from Ser 218 to Thr 225 .
- the IgGl was subjected to H 2 O 2 attack after some pretreatments. These include N-ethyl-maleimide (NEM) pretreatment to block unpaired Cys residues prior to H 2 O 2 treatment, or adding catalase or ethylene-diamine-tetra-acetic acid (EDTA) into the reaction system. SEC was performed to measure the impact. It was found that catalase almost completely blocked cleavage, strongly indicating that the OH radicals were important for cleavage.
- NEM N-ethyl-maleimide
- EDTA ethylene-diamine-tetra-acetic acid
- DMPO 5,5-dimethyl-l-pyrroline JV-oxide
- IgG 1 bulk antibody contains ⁇ 1 % of a truncated antibody (Pl), which was determined to be a heavily oxidized form, with one of the Fab domains missing.
- Pl truncated antibody
- LC-MS/MS analysis identified a small amount of CyS-SO 3 H at Cys 226 in both the intact hinge peptide (THT CyS 226 PPCAPELLGGPSVFLFPPKPK) (SEQ ID NO:5) and the truncated hinge peptide (CyS 226 PPCAPELLGGPSVFLFPPKPK) (SEQ ID NO:6).
- adducts were identified in the N-terminal hinge region of the Fc domain as either isocyanate or N- ⁇ -ketoacyl derivatives that introduced an additional mass of 45 or 71 Da, respectively.
- the IgGl contains -0.28 mol/mol antibody unpaired Cys residues, which are not critical for the cleavage reaction as demonstrated by the fact that blocking all unpaired Cys residues caused no or only little effect on the fragmentation.
- DMPO radical spin trap 5,5'-dimethyl-l-pyrroline N-oxide
- H 2 O 2 induced cleavage of the IgGl, suggesting an involvement of transition metals in the reaction.
- pretreatment did not completely block the cleavage with H 2 O 2 still capable of cleaving the IgGl, despite having a slower reaction rate.
- transition metals e.g., Cu 2+ and Fe 3+
- the metal accelerates the reaction by catalyzing the generation of hydroxyl radicals through a Fenton-like reaction.
- This example proposes a mechanism of radical-mediated Fc fragmentation.
- Our experimental results of studying a human IgGl revealed a radical mediated hinge fragmentation in this human IgGl antibody.
- the trace amount of transition metal catalyzes the generation of OH radicals in the reaction system.
- Reaction of the IgGl antibody with OH radicals resulted in the breakage of the inter-chain disulfide bond between the two cysteine residues located at position 226 (Cys 226 ) in the hinge region (Cys 226 -Pro-Pro-Cys-Pro) of the antibody.
- the disulfide bond breakage was followed by the formation of sulfenic acid (Cys 226 -SOH) and a thiyl radical (Cys 226 -S » ).
- the observed +71 Da adduct at the N-terminus of Thr 225 could have been yielded from the oxidative degradation of His 224 .
- hydrolysis of these unstable intermediates would be another way to recycle them, and this process resulted in some truncated hinge peptides that contain regular N-terminal residues.
- the +45 Da and +71 Da adducts at the N-terminal residues of the upper hinge region are the products of radical cleavage at the ⁇ -carbon of the protein backbone and ⁇ -carbon position of a amino acid side chain, respectively, confirming a radical mediated mechanism for protein backbone cleavage.
- This example demonstrates the resistance to radical-mediated fragmentation by mutation of the His and Lys residues in the hinge core sequence.
- the seven mutants were: Lys 222 Ser (K/S), LyS 222 GIn (K/Q), LyS 222 AIa (K/A), His 224 Ser (WS), HiS 224 GIn (WQ), HiS 224 AIa (WA) and Lys 222 Ser/His 224 Ser (K/S+H/S).
- replacing His with GIn or Ser almost totally blocked (> 97%) OH radical induced fragmentation that led to a release of the Fab domain (C2) and the partial molecule Cl .
- the His/Ala mutation showed ⁇ 6% of fragmentation vs -15% for the native IgGl over a 8-day incubation period.
- all single Lys mutants promoted the cleavage by 31-33%.
- the double mutant K/S+H/S showed a > 97% inhibition of fragmentation, the same percentage measured for the single His/Ser or His/Gin mutant, indicating the importance of the His residue in the fragmentation.
- the His/ Ala mutant showed cleavage, it was not known whether the mutant did comprise the same structural degradations. It had been documented that the LC and HC remain strongly associated without the inter-disulfide bond connecting them (Bigelow. C. et al, Biochemistry, 13: 4602-4609, 1978). Therefore, it is possible that the LC and HC are held together without the inter-disulfide bond and show a similar SEC profile as the Fab domain fragment. Therefore, the mutants were further examined by RP-HPLC-TOF/MS under non- reducing conditions after 1-day OfH 2 O 2 treatment. Under these conditions, it is expected that only non-covalently bonded components would be separated from the main species. As shown in Fig.
- the hinge region where the two hinge inter-disulfide bonds connect the two HC with the upper hinge (DKTHT) (SEQ ID NO: 7) connecting to the Fab domain is a double stranded structure that restrains the hinge to adopt a conformation that is most likely very different than the conformation of the synthetic peptide in solution. Consequently, results obtained from a peptide need to be taken with caution when applied to a protein that contains the same or similar sequence. Taken together, our results clearly indicated that the His/Ser and His/Gin mutants, but not the His/Ala mutant inhibited the OH radical mediated cleavage.
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2010239216A AU2010239216B2 (en) | 2009-04-21 | 2010-04-21 | Fragmentation resistant IgG1 Fc-conjugates |
JP2012507359A JP2012524545A (en) | 2009-04-21 | 2010-04-21 | Fragmentation resistant IgG1 Fc-conjugate |
MX2011010814A MX2011010814A (en) | 2009-04-21 | 2010-04-21 | FRAGMENTATION RESISTANT IgG1 Fc-CONJUGATES. |
EP10715636A EP2421897A1 (en) | 2009-04-21 | 2010-04-21 | FRAGMENTATION RESISTANT IgG1 Fc-CONJUGATES |
US13/265,833 US20120039880A1 (en) | 2009-04-21 | 2010-04-21 | FRAGMENTATION RESISTANT IgG1 Fc-CONJUGATES |
CA2758524A CA2758524A1 (en) | 2009-04-21 | 2010-04-21 | Fragmentation resistant igg1 fc-conjugates |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17139309P | 2009-04-21 | 2009-04-21 | |
US61/171,393 | 2009-04-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2010124018A1 true WO2010124018A1 (en) | 2010-10-28 |
Family
ID=42235770
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2010/031933 WO2010124018A1 (en) | 2009-04-21 | 2010-04-21 | FRAGMENTATION RESISTANT IgG1 Fc-CONJUGATES |
Country Status (7)
Country | Link |
---|---|
US (1) | US20120039880A1 (en) |
EP (1) | EP2421897A1 (en) |
JP (1) | JP2012524545A (en) |
AU (1) | AU2010239216B2 (en) |
CA (1) | CA2758524A1 (en) |
MX (1) | MX2011010814A (en) |
WO (1) | WO2010124018A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8871204B2 (en) | 2010-12-23 | 2014-10-28 | Janssen Biotech, Inc. | Active protease-resistant antibody FC mutants |
EP2990485A4 (en) * | 2013-04-25 | 2017-01-11 | Kaneka Corporation | Fd chain gene or l chain gene each capable of increasing secretion amount of fab-type antibody |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG11201507429TA (en) | 2013-03-15 | 2015-10-29 | Genentech Inc | Il-22 polypeptides and il-22 fc fusion proteins and methods of use |
EP3068797B1 (en) | 2013-11-11 | 2020-01-08 | Wake Forest University Health Sciences | Constructs for multi-valent targeting of tumors |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009006520A1 (en) * | 2007-07-03 | 2009-01-08 | Medimmune, Llc | Hinge domain engineering |
WO2009012600A1 (en) * | 2007-07-26 | 2009-01-29 | Novagen Holding Corporation | Fusion proteins |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1737890A2 (en) * | 2004-03-24 | 2007-01-03 | Xencor, Inc. | Immunoglobulin variants outside the fc region |
-
2010
- 2010-04-21 JP JP2012507359A patent/JP2012524545A/en active Pending
- 2010-04-21 CA CA2758524A patent/CA2758524A1/en not_active Abandoned
- 2010-04-21 US US13/265,833 patent/US20120039880A1/en not_active Abandoned
- 2010-04-21 MX MX2011010814A patent/MX2011010814A/en active IP Right Grant
- 2010-04-21 EP EP10715636A patent/EP2421897A1/en not_active Withdrawn
- 2010-04-21 WO PCT/US2010/031933 patent/WO2010124018A1/en active Application Filing
- 2010-04-21 AU AU2010239216A patent/AU2010239216B2/en not_active Ceased
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009006520A1 (en) * | 2007-07-03 | 2009-01-08 | Medimmune, Llc | Hinge domain engineering |
WO2009012600A1 (en) * | 2007-07-26 | 2009-01-29 | Novagen Holding Corporation | Fusion proteins |
Non-Patent Citations (48)
Title |
---|
ALLEN, G.; CAMPBELL, R., INT. J. PEPTIDE PROTEIN RES., vol. 48, 1996, pages 265 - 273 |
BARON ET AL., NUCLEIC ACIDS RES., vol. 23, 1995, pages 3605 - 3606 |
BERLETT, B. S.; STADTMAN, E. R., J. BIOL. CHEM., vol. 272, 1997, pages 20313 - 20316 |
BIANCHI, A. A.; MCGREW, J. T.: "High-level expression of full antibodies using trans-complementing expression vectors", BIOENGINEERING AND BIOTECHNOLOGY, vol. 84, no. 4, 2003, pages 439 - 444 |
BIGELOW, C. ET AL., BIOCHEMISTRY, vol. 13, 1978, pages 4602 - 4609 |
BIGELOW. C. ET AL., BIOCHEMISTRY, vol. 13, 1978, pages 4602 - 4609 |
BONIFACIC, M. ET AL., J. CHEM. SOC. PEKIN TRANS., vol. 2, 1975, pages 675 - 685 |
BURLING, F. T. ET AL., SCIENCE, vol. 271, 1996, pages 72 - 77 |
CLAIBORNE, A. ET AL., ADV. PROTEIN CHEM., vol. 58, 2001, pages 215 - 276 |
CLAIBORNE, A., BIOCHEMISTRY, vol. 38, 1999, pages 15407 - 15412 |
DEAN, R. T. ET AL., FREE RADICAL RES. COMMUN., vol. 7, 1989, pages 97 - 103 |
EDELMAN ET AL., PROC. NATL. ACAD. SCI. USA, vol. 63, 1969, pages 78 - 85 |
ELLIOT, A. J. ET AL., J. PHYS. CHEM., vol. 85, 1981, pages 68 - 75 |
GARRISON, W. M., CHEM. REV., vol. 87, 1987, pages 381 - 398 |
GILES, G. 1.; JACOB, C., BIOI. CHEM., vol. 383, 2002, pages 375 - 388 |
GILES, N. M. ET AL., CHEMISTRY & BIOLOGY, vol. 10, 2003, pages 677 - 693 |
GLUZMAN ET AL., CELL, vol. 23, 1981, pages 175 |
GOLDENBERG, D. M. ET AL., CANCER RES., vol. 41, 1981, pages 4354 - 4360 |
HARMAN, L. S. ET AL., J. BIOL. CHEM., vol. 259, 1984, pages 5606 - 5611 |
HOME, C. ET AL., J. BIOL. CHEM., vol. 129, 1982, pages 660 - 664 |
JACOB, C. ET AL., BIOL. CHEM., vol. 387, 2006, pages 1385 - 1397 |
KAUFMAN, R. J.; SHARP, P. A., MOL. BIOL., vol. 159, 1982, pages 601 - 621 |
KICE, J. L, ADV. PHYS. ORG. CHEM., vol. 17, 1980, pages 65 |
KIM, J. R. ET AL., ANAL. BIOCHEM., vol. 283, 2000, pages 214 |
MICHAELSEN, T. E. ET AL., PROC. NATL. ACAD. SCI. USA, vol. 91, 1994, pages 9243 - 9247 |
PAGET, M. S. B.; BUTTNER, M. J., ANNU. REV. GENET., vol. 37, 2003, pages 91 - 121 |
PAGET, M.; BUTTNER, M., ANNU. REV. GENET., vol. 37, 2003, pages 91 - 121 |
PHILIP, E., FREE RAD. BIOL. MED., vol. 40, 2006, pages 1889 - 1899 |
POOLE, L. B. ET AL., ANNU. REV. PHARMACOL. TOXICOL., vol. 44, 2004, pages 325 - 347 |
RASMUSSEN ET AL., CYTOTECHNOLOGY, vol. 28, 1998, pages 31 |
RHEE, S. G. ET AL., SCI. STKE, 2000 |
SALMCCN, A., NATURE, vol. 423, 2003, pages 769 - 773 |
SALMEEN, A. ET AL., NATURE, vol. 423, 2003, pages 769 - 773 |
SAPHIRE, E. ET AL., J. MOL. BIOL., vol. 319, 2002, pages 9 - 18 |
SMITH, M. A. ET AL., INT. J. PEPT. PROTEIN RES., vol. 48, 1996, pages 48 - 55 |
STADTMAN. E. R.; LEVINE, R. L., AMINO ACIDS, vol. 25, 2003, pages 207 - 218 |
STAMLER, J. S.; HAUSLADEN A., NAT. STRUCT. BIOL., vol. 5, 1998, pages 247 - 251 |
STANFIELD, R. ET AL., SCIENCE, vol. 248, 1990, pages 712 - 719 |
THORPE ET AL.: "The Preparation And Cytotoxic Properties Of Antibody-Toxin Conjugates", IMMUNOL. REV., vol. 62, 1982, pages 119 - 158 |
UCHIDA, K.; KAWAKISHI, S., BIOCHEM. BIOPHYS. RES. COMMUN., vol. 138, 1986, pages 659 - 665 |
URLAUB ET AL., PROC. NATL. ACAD. SCI. USA, vol. 77, 1980, pages 4216 - 4220 |
URLAUB; CHASIN, PROC. NATL. ACAD. SCI. USA, vol. 77, 1980, pages 4216 - 4220 |
WEIK, M. ET AL., PROC. NATL. ACAD. SCI. USA, vol. 97, 2000, pages 623 - 628 |
WITTING, P. K.; MAUK, A. G., J. BIOL. CHEM., vol. 276, 2001, pages 16540 - 16547 |
YAN BOXU ET AL: "Human IgG1 Hinge Fragmentation as the Result of H2O2-mediated Radical Cleavage", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 284, no. 51, December 2009 (2009-12-01), pages 35390 - 35402, XP007913455, ISSN: 0021-9258 * |
YATES ZAC ET AL: "Histidine residue mediates radical-induced hinge cleavage of human IgG1.", THE JOURNAL OF BIOLOGICAL CHEMISTRY 11 JUN 2010 LNKD- PUBMED:20304919, vol. 285, no. 24, 11 June 2010 (2010-06-11), pages 18662 - 18671, XP007913457, ISSN: 1083-351X * |
ZHANG, H. ET AL., J. BIOL. CHEM., vol. 280, 2005, pages 40684 - 40698 |
ZHANG, N. ET AL., J. PHYS. CHEM., vol. 95, 1991, pages 4718 - 4722 |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8871204B2 (en) | 2010-12-23 | 2014-10-28 | Janssen Biotech, Inc. | Active protease-resistant antibody FC mutants |
US9611328B2 (en) | 2010-12-23 | 2017-04-04 | Janssen Biotech, Inc. | Active protease-resistant antibody FC mutants |
EP2990485A4 (en) * | 2013-04-25 | 2017-01-11 | Kaneka Corporation | Fd chain gene or l chain gene each capable of increasing secretion amount of fab-type antibody |
US10570197B2 (en) | 2013-04-25 | 2020-02-25 | Kaneka Corporation | Fd chain gene or L chain gene capable of increasing secretion amount of fab-type antibody |
Also Published As
Publication number | Publication date |
---|---|
AU2010239216B2 (en) | 2012-07-12 |
AU2010239216A1 (en) | 2011-10-27 |
JP2012524545A (en) | 2012-10-18 |
EP2421897A1 (en) | 2012-02-29 |
CA2758524A1 (en) | 2010-10-28 |
MX2011010814A (en) | 2011-10-28 |
US20120039880A1 (en) | 2012-02-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US12037408B2 (en) | Method of treating a tumor using anti-TfR antibodies | |
TWI767899B (en) | Psma and cd3 bispecific t cell engaging antibody constructs | |
TWI828040B (en) | Bispecific t cell engaging antibody constructs | |
CN108350073B (en) | Monoclonal antibodies against BCMA | |
JP2023509351A (en) | Antibody-conjugated BCMA and uses thereof | |
CN110526971B (en) | anti-CD 38 antibodies and fusions with attenuated interferon alpha-2B | |
CN110475570B (en) | Anti-human annexin A1 antibodies | |
CN105492462B (en) | Lectin-like oxidized LDL receptor 1 antibodies and methods of use | |
SG178712A1 (en) | Human antibodies that bind cxcr4 and uses thereof | |
JP7514363B2 (en) | Antibodies to IL-7R alpha subunit and uses thereof | |
AU2010239216B2 (en) | Fragmentation resistant IgG1 Fc-conjugates | |
CA3067735A1 (en) | Method of purifying glycosylated protein from host cell galectins and other contaminants | |
AU2020266283A1 (en) | Antibodies binding to plasmodium circumsporozoite protein and uses thereof | |
CN112313250A (en) | Variant antibodies that bind CD38 | |
RU2811912C2 (en) | Antibodies against il-7r alpha subunit and their use | |
KR20170099963A (en) | Antibodies that bind human c6 and uses thereof | |
WO2023108115A1 (en) | Ph-selective antibody fc domains | |
CN118434768A (en) | Agonistic LTBR antibodies and bispecific antibodies comprising them |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10715636 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2758524 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2011/010814 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2012507359 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13265833 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 2010239216 Country of ref document: AU Date of ref document: 20100421 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010715636 Country of ref document: EP |